Loading data
PCRXNasdaq
| Unit: USD | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 726.41 m USD | 700.97 m USD | 674.98 m USD | 666.82 m USD | 541.53 m USD |
| Cost of revenue | 149.75 m USD | 170.43 m USD | 184.67 m USD | 199.3 m USD | 140.26 m USD |
| Research and development expense | 117.31 m USD | 81.58 m USD | 76.26 m USD | 84.8 m USD | 55.55 m USD |
| Selling, general and administrative expense | 368.76 m USD | 294.1 m USD | 269.44 m USD | 254.52 m USD | 199.35 m USD |
| Operating profit | 19.19 m USD | -73.37 m USD | 87.68 m USD | 60.02 m USD | 89.92 m USD |
| Interest expense | — | — | 20.31 m USD | 39.98 m USD | 31.75 m USD |
| Profit before tax | 16.87 m USD | -63.11 m USD | 61.7 m USD | 13.3 m USD | 56.4 m USD |
| Income tax expense | 9.84 m USD | 36.45 m USD | 19.75 m USD | -2.61 m USD | 14.42 m USD |
| Net income (reported basis) | 7 m USD | -99.6 m USD | 42 m USD | 15.9 m USD | 42 m USD |
| Basic earnings per share | 0.16 USD/share | -2.15 USD/share | 0.91 USD/share | 0.35 USD/share | 0.95 USD/share |
| Diluted earnings per share | 0.16 USD/share | -2.15 USD/share | 0.89 USD/share | 0.34 USD/share | 0.92 USD/share |
Quotes are end-of-day data. Content is for research purposes and is not investment advice.